Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15837550 | 0.81 | CA12 (0.51) | MAOBTRPA1TSHRKIF11IDO1 | |
| SCHEMBL31463164 | 0.80 | TSHR (0.57) | MAOBTSHRKIF11PDK2IDO1 | |
| SCHEMBL31432929 | 0.78 | TRPA1 (0.46) | TRPA1 | |
| SCHEMBL4873147 | 0.78 | TRPA1 (0.46) | TRPA1 | |
| SCHEMBL11996571 | 0.76 | TSHR (0.44) | MAOBTSHRKIF11IDO1PTGS1 | |
| SCHEMBL3422469 | 0.76 | TSHR (0.59) | MAOBTSHRKIF11PDK2IDO1 | |
| SCHEMBL31245798 | 0.75 | CYP11B1 (0.47) | MAOBTSHRKIF11PDK2MMP3 | |
| SCHEMBL16817007 | 0.75 | TSHR (0.46) | MAOBTSHRKIF11PDK2IDO1 | |
| SCHEMBL4333682 | 0.75 | CYP11B1 (0.47) | MAOBTSHRKIF11PDK2MMP3 | |
| Hydrogen Sulfide SCHEMBL27511889 | 0.74 | TSHR (0.56) | MAOBTSHRKIF11PDK2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044041-A1 | 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives | KUDUK SCOTT D (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044041-A1 | 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives | BDKRB1, BDKRB2, LTB4R2 | MAOB 617/4885TRPA1 9/4885TSHR 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.